IV Secukinumab Rapidly Improved Clinical Responses in Psoriatic Arthritis
Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.
Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.
NEJM Group’s Dr. Lauren Westafer talks with study author Dr. Luca Giurgea about BPL-1357, an investigational universal influenza vaccine that appeared safe and well tolerated…
Current evidence is insufficient to recommend routinely dosing blood pressure medications in the evening instead of morning. Clinicians should base dosing practice on patient risk…
Does it feel like whenever you close your eyes to get some sleep, there’s a movie playing on repeat in your head without your permission?…
RING-Bait technology hijacks the process of templated aggregation to recruit ubiquitination machinery and selectively degrade pathogenic tau assemblies without generating a specific binder, thereby reducing…
Comprehensive genomic testing is beneficial for patients at all stages of lung adenocarcinoma, according to a recent study.
A case report details one man’s head injury from breakdancing
The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical…
Hospitals are deploying strategies to conserve medical IV solutions after Baxter’s North Carolina facility was damaged by Hurricane Helene.
Multiwavelength photobiomodulation significantly lowered the risk of vision loss and geographic atrophy in eyes with dry age-related macular degeneration.
When trusted professionals speak up, people listen Over the past century, Earth’s average temperature has risen by more than 1.3°C, a clear sign that something…